Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Brown University
Brown University
Yonsei University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
National Cancer Center Hospital East
NRG Oncology
Spanish Breast Cancer Research Group
MedSIR
SOLTI Breast Cancer Research Group
Jiangsu HengRui Medicine Co., Ltd.
Seagen Inc.
AstraZeneca
Gruppo Oncologico del Nord-Ovest
MedSIR
AstraZeneca
Yale University
AstraZeneca
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Henan Cancer Hospital
Gruppo Oncologico del Nord-Ovest
Yonsei University
Shanghai Jiao Tong University School of Medicine
Fudan University